PrEP stands for pre-exposure prophylaxis. When taken consistently, PrEP reduces the risk of getting HIV from sex by approximately 99 percent and from injection drug use by more than 74 percent. Four FDA-approved PrEP options exist in 2026: Truvada (emtricitabine/TDF, daily oral pill with generic available), Descovy (emtricitabine/TAF, daily oral pill), Apretude (cabotegravir, injection every two months), and Yeztugo (lenacapavir, injection every six months). The appropriate option depends on the patient's risk profile, anatomy, and preference, which requires a clinical conversation. Generic emtricitabine/TDF is clinically identical to brand Truvada and costs approximately $25 to $30 per month with a pharmacy discount coupon, making it the lowest-cost option for uninsured patients who don't qualify for a patient assistance program.
For patients with private insurance in 2026, PrEP should cost $0. Section 2713 of the Affordable Care Act requires most private health insurance plans to cover USPSTF Grade A preventive services without any patient cost-sharing. The USPSTF assigns PrEP a Grade A recommendation for HIV prevention. On June 27, 2025, the Supreme Court upheld this requirement in Kennedy v. Braidwood Management, ruling 6-3 that the ACA's no-cost-sharing mandate is constitutional. If your insurer is charging you a copay or applying a deductible to a PrEP prescription or related lab visit, that is likely a billing error or formulary misclassification. Use the medical bill analyzer to review the charge. You can also file a complaint with your state insurance department.
Medicare beneficiaries gained PrEP coverage under Part B effective September 30, 2024. Under this coverage, Medicare pays for FDA-approved oral and injectable PrEP medications, administration of the injectable forms, HIV risk counseling (up to 8 visits per year), and required labs, all without any deductible, copay, or coinsurance. Previously, oral PrEP was covered under Medicare Part D, which required cost-sharing. The transition to Part B is significant: Medicare Part B covers PrEP as a preventive service with zero cost-sharing, not subject to the Part B deductible of $283 in 2026. Patients who see Descovy or Truvada billed under Part D on their Medicare Explanation of Benefits after September 30, 2024 may be experiencing a coding error and should contact their plan. The Inflation Reduction Act's $2,100 annual Part D out-of-pocket cap applies to other medications these patients may be taking, but PrEP itself now sits under Part B.
What PrEP Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same prep can cost many times more at a hospital than at your local pharmacy:
2026 PrEP Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Private insurance (ACA-compliant plan, 2026) | $0 (no deductible, no copay, no coinsurance) | ACA Section 2713 requires zero cost-sharing for USPSTF Grade A preventive services. PrEP is Grade A. Upheld by Kennedy v. Braidwood (June 2025). |
| Medicare Part B (2026) | $0 (oral and injectable PrEP covered as preventive service) | Effective September 30, 2024. Covers medication, labs, and up to 8 counseling visits per year. Not subject to the $283 Part B deductible. |
| Pharmacy counter (retail, cash) - brand Descovy or Truvada | $2,022 - $2,944 per 30-day supply | Brand-name cash prices without any assistance in 2026. Gilead PAP can reduce to $0 for eligible uninsured patients. |
| Pharmacy counter (retail, cash) - generic emtricitabine/TDF | $25 - $30 per 30-day supply (with GoodRx or discount coupon) | Generic Truvada (emtricitabine/TDF) is the lowest cash-pay option. Clinically equivalent to brand Truvada for most indications. |
| Medicaid | $0 - $4 per prescription (PrEP covered as preventive service) | Medicaid expansion programs must cover USPSTF Grade A preventive services without cost-sharing per ACA. Coverage varies by state for Medicaid non-expansion. |
Prices reflect 2026 data from GoodRx, Gilead, and CMS. Brand prices and generics fluctuate by pharmacy. The ACA zero-cost-sharing requirement applies to all ACA-compliant plans including most employer-sponsored plans and ACA Marketplace plans.
Source: CMS Medicare PrEP coverage page, ACA Section 2713, GoodRx 2026 pricing, Gilead Advancing Access
Why Hospitals Charge So Much
PrEP is primarily an outpatient prescription drug for self-administration at home, so inpatient hospital charges for PrEP are uncommon. When PrEP does appear on an itemized hospital bill, it is usually because the patient was admitted for another reason and the hospital dispensed a short supply to prevent a gap in prevention, or because injectable PrEP (Apretude or Yeztugo) was administered during an outpatient clinical visit. Hospital facility fees routinely stack on top of the drug acquisition cost, pharmacy handling charges, and nursing administration fees, which can push a single dose of injectable PrEP from a clinic-rate of roughly $4,139 for Apretude into a hospital line item of $8,000 or more.
If you see PrEP on an inpatient or outpatient facility bill with charges far above the drug's retail or clinic rate, request an itemized bill with the National Drug Code (NDC) and the specific HCPCS service code. Under Medicare Part B, PrEP is covered as a preventive service with $0 cost-sharing, so any facility charge for PrEP for a Medicare beneficiary should be zero except in very narrow circumstances. For commercially insured patients under an ACA-compliant plan, charges above $0 for PrEP itself are a likely billing error. Document the charge, compare the NDC to the dispensed drug, and use your plan's formal dispute process.
Three structural factors drive facility PrEP markups when they do occur. First, hospitals negotiate drug acquisition costs differently from retail pharmacies, and brand-name PrEP drugs like Descovy and Yeztugo carry high wholesale list prices ($2,200 to $28,218 per year). Second, facility fees for clinical services, HIV counseling, and drug administration are often billed separately under procedure codes and are not included in pharmacy-counter comparisons. Third, under outpatient prospective payment (OPPS), Medicare pays hospitals a bundled rate rather than a per-drug ASP rate. Patients comparing their bill to retail GoodRx prices may see large apparent discrepancies that reflect the billing structure, not necessarily overcharging. Always request an itemized Explanation of Benefits from your insurer and compare line-by-line.
Patient Assistance Programs
Uninsured patients who do not qualify for Medicaid and cannot afford brand-name PrEP have several routes to free or low-cost medication in 2026. The Gilead Advancing Access Medication Assistance Program is the primary route for Descovy and Yeztugo. ViiV Healthcare operates a separate program for Apretude (cabotegravir injectable). State ADAP (AIDS Drug Assistance Programs) programs, operating in all 50 states plus Washington DC and U.S. territories, also cover PrEP medications. Note that the federal Ready, Set, PrEP program ended July 18, 2025 and is no longer accepting enrollments.
Patient assistance programs for PrEP| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Gilead Advancing Access Medication Assistance Program (MAP) | Free Descovy or Yeztugo for uninsured patients earning at or below 500% FPL (~$79,800/year for a household of 1 in 2026). No Social Security number required. Undocumented residents are explicitly eligible. | advancingaccessconsent.iassist.com or call 1-800-226-2056 |
| Gilead Advancing Access Co-pay Savings Program | $0/month or up to $7,200/year in copay assistance for commercially-insured patients taking Truvada, Descovy, or Yeztugo. No income restriction for the copay savings program. | prep.advancingaccess.com or call 1-800-226-2056 |
| ViiV Healthcare Patient Assistance Program (for Apretude) | Free Apretude (cabotegravir injectable) for uninsured patients earning at or below 500% FPL. Medication only (does not cover clinic visit costs for administering the injection). | gskpaf.org/viiv or call 1-844-588-3288 |
| State ADAP (AIDS Drug Assistance Program) | Free or low-cost PrEP, labs, and clinical visits in all 50 states, Washington DC, and U.S. territories. Income eligibility varies by state (typically 200-400% FPL). Some states also cover provider visits and required labs. | nastad.org/prep-access/prep-assistance-programs |
| Federally Qualified Health Centers (FQHCs) | Sliding-scale PrEP services (medication, labs, and clinical visits) based on ability to pay. Approximately 14,000 FQHC sites nationwide. No insurance or immigration status requirements. | findahealthcenter.hrsa.gov |
Manufacturer co-pay savings cards and manufacturer coupon programs (Gilead Advancing Access Co-pay Savings Program) are not available to Medicare, Medicaid, TRICARE, or VA beneficiaries by federal anti-kickback statute (42 U.S.C. § 1320a-7b). If you have government insurance, apply for the Gilead MAP or use your Medicare Part B or Medicaid zero-cost coverage instead. The federal Ready, Set, PrEP program (getyourprep.com) ended July 18, 2025 and is no longer enrolling patients.
Source: Gilead Advancing Access, ViiV Healthcare Patient Assistance Program, NASTAD ADAP directory, HRSA Find a Health Center, HIV.gov
Medicare Part D
PrEP shifted from Medicare Part D to Medicare Part B effective September 30, 2024. Under Part B, PrEP is covered as a preventive service with zero cost-sharing. Medicare beneficiaries do not pay the Part B deductible of $283 (2026) for PrEP, do not pay any coinsurance, and do not pay a copay. This includes oral PrEP medications (Truvada, generic emtricitabine/TDF, Descovy), injectable PrEP (Apretude, Yeztugo), HIV counseling visits, and required lab tests including HIV tests and kidney function panels. If your Medicare Part D plan is still processing PrEP claims, notify your plan and prescriber about the Part B transition.
Medicare Part D still applies to a beneficiary's other medications. The 2026 Part D annual out-of-pocket cap is $2,100 under the Inflation Reduction Act. PrEP spending no longer counts toward the Part D out-of-pocket cap because PrEP has moved to Part B. Medicare beneficiaries who are also taking HIV treatment drugs (antiretrovirals for an existing HIV-positive diagnosis) should verify with their Part D plan whether those treatment drugs are still Part D or have also been reclassified, as coverage structures differ for treatment versus prevention.
Common PrEP Billing Errors
If you received a bill for PrEP in 2026 with any out-of-pocket cost under a commercial plan or Medicare, check for these common errors before paying:
- PrEP billed under a formulary tier (Tier 3 specialty) instead of as a no-cost-sharing preventive service. Commercial plans must cover PrEP at $0 regardless of formulary tier under ACA Section 2713.
- Deductible applied to PrEP before the deductible is met. ACA preventive services are exempt from the deductible. PrEP cannot be subject to a formulary tier deductible requirement.
- PrEP billed under Medicare Part D instead of Medicare Part B after September 30, 2024. If your Medicare Explanation of Benefits shows PrEP under Part D, call your plan to correct the claim.
- Lab tests required for PrEP monitoring (HIV test, creatinine, hepatitis B screening) billed separately at cost-sharing rates when they should be covered at $0 as part of the preventive PrEP service.
- Generic emtricitabine/TDF billed at brand Truvada's retail cash price. If you are taking the generic, confirm the NDC number on the pharmacy receipt matches a generic manufacturer (Teva, Lupin, Amneal, etc.), not Gilead.
- Prior authorization denial without appeal. Some plans incorrectly require prior authorization for PrEP even though it should be covered without restrictions as a preventive service. File a PA waiver request citing ACA Section 2713 and USPSTF Grade A.
Frequently Asked Questions
Is there a generic for PrEP in 2026?
Yes, for one of the four FDA-approved PrEP options. Generic emtricitabine/tenofovir disoproxil fumarate (generic Truvada) has been available since 2020 and costs approximately $25 to $30 per month with a GoodRx coupon in 2026. This is the most affordable cash-pay PrEP option. No commercial generic for Descovy (emtricitabine/TAF) is available in the U.S. as of June 2026, despite an April 2026 FDA approval, due to pending patent disputes. No generic exists for injectable Apretude (cabotegravir) or Yeztugo (lenacapavir).
How do I apply for the Gilead Advancing Access patient assistance program for PrEP?
Visit advancingaccessconsent.iassist.com or call 1-800-226-2056 (Monday through Friday, 9 AM to 8 PM ET). Select 'Uninsured Support' and then 'PAP Eligibility Screening.' You will need proof of income (tax return or pay stubs), proof of U.S. residency, a valid PrEP prescription, and a statement that you have no prescription drug insurance. No Social Security number is required, and undocumented residents are eligible. Approval typically takes 5 to 10 business days. The income limit is 500% FPL, which is approximately $79,800 per year for a household of one in 2026.
Can I use the Gilead PrEP savings card with Medicare?
No. The Gilead Advancing Access Co-pay Savings Program is for commercially-insured patients only. Federal anti-kickback statute (42 U.S.C. § 1320a-7b) bars manufacturer copay cards from being used by anyone enrolled in Medicare, Medicaid, TRICARE, or VA benefits. If you have Medicare, your PrEP is covered at $0 under Medicare Part B as of September 30, 2024. If you also have no Medicare drug coverage for PrEP and are uninsured for other reasons, apply for the income-based Gilead MAP instead of the copay savings card.
What if my insurance denies coverage for PrEP?
A denial for PrEP coverage under an ACA-compliant plan is likely improper. Under ACA Section 2713, all ACA-compliant insurance plans must cover USPSTF Grade A preventive services at $0. PrEP is a Grade A recommendation. File a formal internal appeal citing ACA Section 2713 and the USPSTF Grade A rating. Ask your prescriber for a peer-to-peer review. If the internal appeal fails, request an external independent review through your state insurance department. While appealing, you can obtain the generic at roughly $30 per month cash or apply for the Gilead MAP if you meet the income threshold.
Does the IRA negotiated price apply to PrEP?
No. None of the four FDA-approved PrEP drugs (Truvada, Descovy, Apretude, Yeztugo) were selected for Medicare drug price negotiation in Round 1 (effective 2026-01-01) or Round 2 (effective 2027-01-01) under the Inflation Reduction Act of 2022. No Maximum Fair Price has been set for any PrEP medication. However, Medicare beneficiaries still pay $0 for PrEP because PrEP is covered under Medicare Part B as a preventive service with zero cost-sharing, which is a separate and more powerful protection than the IRA negotiated price mechanism. Unlike the IRA Maximum Fair Price (which applies at the Part D pharmacy counter), PrEP's Part B zero-cost coverage means no deductible, no coinsurance, and no copay.
What does PrEP cost without insurance at the pharmacy counter in 2026?
Cash prices for PrEP without insurance in 2026 vary widely by drug. Generic emtricitabine/TDF (generic Truvada) costs approximately $25 to $30 per month with a GoodRx coupon at major pharmacies. Brand Descovy runs $2,162 at Kroger to $2,229 at Walgreens per month without assistance. Brand Truvada retails around $2,022 per month. Injectable Yeztugo has a list price of approximately $28,218 per year ($2,352 per month equivalent). The vast majority of patients should not be paying these cash prices. If you have private insurance, PrEP should cost $0. If uninsured, apply for the Gilead MAP or find a local FQHC.
Do I qualify for the Gilead Advancing Access patient assistance program?
You qualify for the Gilead MAP if you meet all of: you are uninsured (no active prescription drug coverage), your household income is at or below 500% of the federal poverty level (approximately $79,800 per year for a household of one in 2026, rising with household size), you reside in the U.S. (including undocumented residents; no Social Security number required), and you have a valid PrEP prescription from a U.S.-licensed provider. If you have Medicare, Medicaid, or commercial insurance, you do not qualify for the MAP but may use the Medicare Part B zero-cost benefit, Medicaid coverage, or the commercial copay savings program instead.
What happened to the federal Ready, Set, PrEP program?
The federal Ready, Set, PrEP program, which provided free PrEP to uninsured Americans at getyourprep.com, ended on July 18, 2025. Gilead discontinued free Truvada contributions to the program in January 2025, and the program stopped accepting new enrollments in July 2024 before fully closing in July 2025. As of June 2026, the main federal-level free PrEP option is the Gilead Advancing Access Medication Assistance Program for Descovy and Yeztugo. State ADAP programs, Federally Qualified Health Centers, and MISTR telehealth (which coordinates free PrEP through 340B and manufacturer programs) remain available nationwide.
